We’re excited to announce that AminoChain is heading to ISBER 2025, the leading global conference for biobanking and biospecimen research. At this year’s event, May 12th, we’ll be launching the Specimen Center: a new decentralized platform that transforms how researchers and

This year at ISBER, we’re doing more than just showing up — we’re inviting biobanks to help build what comes next. Visit us at Booth #24 to get a live look at the Specimen Center, our new platform designed to streamline how biospecimens are shared, searched, and secured across

Only 3 more days until the ISBER Conference kicks off - and we can’t wait to show you what we’ve been building. Let’s talk about one of the Specimen Center’s most powerful features: Advanced Metadata Search - Find the exact biospecimens you need using structured filters like

Only 2 days to go. On May 12, we’re launching something that’s not just powerful — it’s practical. Let’s talk about accessibility. The Specimen Center was built to move with you - literally. → Mobile-Optimized analytics Interface: Access high-level biobank inventories, review

C-BIGR is the world’s only Open Science biobank and patient registry—home to over 3,000 patient contributions, 120+ cell lines, and CRISPR-repaired controls. It fuels global collaboration in neuroscience research, supporting precision trials in ALS, MS, Parkinson’s, and more.

INO Specimens Biobank, part of the INOVIE Group—France’s major clinical lab network—offers over 20,000 characterized, anonymized specimens (serum, plasma, urine, swabs, stool) from 700+ labs and 27 central facilities. With testing across 600+ biomarkers daily and profiling on

Congrats to Caspar Barnes & the entire AminoChain team!

Congratulations to portfolio company AminoChain on the launch of the AminoChain Specimen Center. 👏 🧬 This platform streamlines access to biospecimens, empowering researchers and biobanks with smart search, built-in compliance, and a faster path from sample discovery to

NDRI (National Disease Research Interchange) is the leading U.S. provider of postmortem human tissues and organs for research. A nonprofit established in 1980, NDRI connects a national network of recovery partners with scientists working to advance treatments and cures across

Ukraine Research Group provides ethically sourced, clinically relevant biospecimens that support biomedical breakthroughs across complex and rare diseases. With 1,910 donors and 6,483 specimens, their collections span a wide disease spectrum and are acquired through a trusted

ProteoGenex is a leading biospecimen provider offering one of the most comprehensive biobank inventories in the world. With over 57,000 donors and 200,000 specimens, including frozen and FFPE tissues, blood, serum, plasma, and more, their collections support a wide range of

You’ve got the research plan. The team is ready. Funding is secured. Deadlines are tight. And then… silence. You’re stuck waiting. On emails, on approvals, on inventory that may or may not exist. Weeks go by. Momentum dies. Opportunities vanish. And for what? A biosample that

If you’ve ever dealt with traditional brokers, you know it can be slow, confusing, and full of extra steps. That’s why we built the AminoChain Specimen Center — to make things easier for everyone involved. → Researchers can search and find what they need faster → Biobanks

Biobanks hold millions of high-value biospecimens (tissue, blood, DNA) all collected, stored, and ready for use. But here’s the twist: most of that value is locked away. Because without visibility, interoperability, and standardized metadata, these samples stay on shelves while

For decades, animal models have been the default in biomedical research, but their limitations have become impossible to ignore. From mice to monkeys, these models often fail to replicate the complex biology of human diseases, leading to treatments that work in the lab but fall

Ask researchers who’ve tried to source biospecimens, and the responses sound painfully familiar: • “I just want to search everything in one place.” • “I need to know if the samples I’m seeing are actually available.” • “Why isn’t there more metadata on these samples?” •

Across the world, biobanks are storing millions of high-value biospecimens. Blood, tissue, DNA - all ready to be used in research. And yet, most of it just sits there. The problem? Most biobanks are stuck using outdated systems that make it nearly impossible for researchers to

What good are samples if no one can find them? Biobanks do the hard part - collecting, storing, maintaining millions of high-value biospecimens. But here’s the catch: most of them can’t be easily searched by the researchers who need them. This is equally true for

It’s a funny question. But also kind of a serious one. NFTs have on-chain metadata, provenance records, and public visibility - built in. Biospecimens? Not so much. Most samples collected for research disappear into opaque systems. Donors never hear what happens to them.

The traditional way to connect biobanks is to centralize everything; pull all the data into one massive system, reformated into one ontology, governed by one entity, with one set of rules. Sounds organized, right? Until it creates just another silo. We believe in a different